IDEAYA Biosciences and Servier Announce Positive Topline Results from Phase 2/3 Registrational Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in First-line HLA-A*02:01-Negative Meta

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/12/2026

1. ADBE
2. SPCX
3. USO
4. SPY
5. RH
6. NVDA
7. RKLB
8. MSFT
9. CRM
10. CRWV

Go back to IDEAYA Biosciences and Servier Announce Positive Topline Results from Phase 2/3 Registrational Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in First-line HLA-A*02:01-Negative Meta

Ideaya Biosciences (IDYA) PT Raised to $52 at Mizuho, 'we recommend being opportunistic'

April 13, 2026 3:08 PM EDT

Mizuho analyst Graig Suvannavejh raised the price target on Ideaya Biosciences (NASDAQ: IDYA) to $52.00 (from $46.00) while maintaining a Outperform rating.

The analyst comments "Following up on Quick Take comments earlier today (LINK) on positive P2/3 data for darovasertib/daro (a protein kinase C/PKC... More

Ideaya Biosciences (IDYA) PT Raised to $65 at Truist Securities

April 13, 2026 2:05 PM EDT

Truist Securities analyst Greg Renza raised the price target on Ideaya Biosciences (NASDAQ: IDYA) to $65.00 (from $60.00) while maintaining a Buy rating.

The analyst comments "Today's disclosure highlights daro's best-in-class PFS and consistent efficacy to an earlier study which together with a favorable OS trend... More